ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PYC Physiomics Plc

1.30
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.30 1.20 1.40 1.30 1.30 1.30 333,263 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 597k -477k -0.0035 -3.71 1.76M
Physiomics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 1.30p. Over the last year, Physiomics shares have traded in a share price range of 0.925p to 4.20p.

Physiomics currently has 135,472,478 shares in issue. The market capitalisation of Physiomics is £1.76 million. Physiomics has a price to earnings ratio (PE ratio) of -3.71.

Physiomics Share Discussion Threads

Showing 26226 to 26246 of 30125 messages
Chat Pages: Latest  1061  1060  1059  1058  1057  1056  1055  1054  1053  1052  1051  1050  Older
DateSubjectAuthorDiscuss
24/8/2020
07:55
TRX still under the Radar.
hodhasharon
23/8/2020
22:02
Yes, block, aka, stick your fingers in your ears, and go 'la la la la I can't hear you'.

Do you realise when you block someone it doesn't work the other way around. We can still see your posts. But if it makes you feel more secure, in your confirmation bias echo chamber safe space, pull the blankets over your head and do it 😂

davevt
23/8/2020
21:45
They add 0 value Hod, just block them.
spudyoulike
23/8/2020
19:13
“What's funny is they say it should be worth 100p, with absolutely zero basis.”

....and the basis offered for a 4p valuation is.....

Bloody newbies...

hodhasharon
23/8/2020
19:09
It's funny reading the posts on lse....'201k buy, people are taking positions!'

Yes dude, that's a bad thing, not a good thing. You have someone now wanting to SELL 201k shares when news comes out. Sells make the price go down or saturate buys, not up 😂

Buys and volume only matter when news comes out, otherwise, it's a bad thing.

davevt
23/8/2020
18:28
What's funny is they say it should be worth 100p, with absolutely zero basis.

May as well say 1000p, it makes no difference.

'We will be trading at 120p by the end of the year'....funny, the rampers have been saying that for the last 3 years.

And here it is, back down in single digits like it always does.

davevt
23/8/2020
18:00
Nothing is certain in this business save to say you will come across Some dipstick rampers/parasites like shoddy and stig.theyknow they have been rumbled but cannot help themselves,hence their Sunday night ramps.100p/200p this year the men in white coats must be knocking on their doors soon.
albert3591
23/8/2020
16:49
Very much looking forward to news from VAL201 as a PYC shareholder

Can see it being transformational news

www.proactiveinvestors.co.uk/companies/amp/news/27661

the stigologist
23/8/2020
15:25
PYC is a certain multi-bagger. We’ll be trading at the 100-120p range by the end of the year.
hodhasharon
23/8/2020
11:47
It is Sunday perhaps they could call on Devine intervention.LOL
albert3591
23/8/2020
11:41
Oh spuds on the ramp too now, talking about things years away, that could well never happen, and would just pay the debt they were owed from ten years ago.

This is the thing, even if it happened, rampers would be like 'oh they got the licencing deal'.....but it's not 'extra' money, it's money they have been owed for TEN YEARS 😂

davevt
23/8/2020
11:39
Cancer AI 'leaders'?

😂😂😂😂 8514;😂ԅ14;😂

OK Stig, just stop. Seriously, I don't think there is any company below pyc. Honestly.

davevt
23/8/2020
11:16
If they haven’t cottoned on they will never do,not worth bothering with in the first place,unless your a parasite ramper that is.
albert3591
22/8/2020
20:59
HUGE news i missed on Friday

AstraZeneca partner with £400m (zero revenue) RENX on Kidney AI

How long before big players cotton on to UK cancer AI leaders Physiomics

the stigologist
22/8/2020
20:57
With VAL due to release results for l&ll clinical trials for VAL201 in the coming weeks, it's worth taking a look at the pre-licensing upfront averages. PYC take a % cut on any deals for work carried out in Pre-clinical trials 10 yrs ago. Globaldata - 2011/2016Big pharma. - ph 1 av £61 million Ph 2 av £125 millionAll Licensors - ph 1 av £45 million Ph 2 av £62 million
spudyoulike
22/8/2020
08:09
So Simulations Plus (Mkt Cap $1bn) have raised $115m for 'strategic M&A'

That is some war-chest.

Even if they don't come knocking for Physiomics (Mkt Cap £7.5m) I expect this continuing Industry M&A to lift valuations across the sector


For Immediate Release:
August 10, 2020

Simulations Plus Announces Closing of Public Offering and Full Exercise of
Underwriters’ Option to Purchase Additional Shares

LANCASTER, CA, August 10, 2020 – Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and
simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced the closing of its
previously announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share, which included the full exercise of
the underwriters’ option to purchase 272,727 additional shares of common stock. The aggregate gross proceeds to Simulations Plus from this offering were
approximately $115 million, before deducting underwriting discounts and commissions and other offering expenses payable by Simulations Plus.

the stigologist
21/8/2020
16:00
I feel hurt now, looks like the redline got breeched oh dear me.
albert3591
21/8/2020
15:18
This board looks so much cleaner after blocking Dave and Albert.
spudyoulike
21/8/2020
15:06
Author: Riddler (LSE) Here are the facts! Sheephatch and new investors: • Market cap £6mln and 98mln shares• 70% compound revenue growth 2017-19 • Last update June 2020• Cash £1.25mln (raised £850k May 2020) + £150k grant May 2020• 98million shares in issue• Record revenues last 3yrs and therefore £790k for 2019 (1/7th of market cap)• Signed significant new major client in July 2020 ,Japanese multi national • More deals expected H2 2020• Jim Millen (CEO ) Joined in 2016 with 15yrs experience across blue chip globals and smaller UK companies. Previously had a Business Development role at GlaxoWhat do they do?Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs."With another record year behind us, we continue our journey to becoming a sustainably profitable business. In the next twelve months we're aiming to execute more projects than ever before and to add further new clients both in the UK, Europe and North America. We expect and indeed welcome a balance between larger and small clients and target a further diversification "2019 developmentsMay 17th ICR announces £75mln for a new UK centre for Artificial intelligence use in cancer research of which PYC will be part of judging by the fact PYC tweeted the article and ICR work with PYC.June 28th• Signs contract with NASDAQ listed and $200mln valued Bicycle GroupJuly 8thSigns a deal with CancerResearch UK and Bicycle group for their lead compound which has $30mln -40mln committed spend for Phase II/ III trialsS"analysis of clinical data arising from the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial of Bicycle Therapeutics' lead program, BT1718, in solid tumours"December 2019• Another renewal with Merck ( whom are working on a $4.2bln+programmme with Glaxo)• A new contract with Cellcentric• A new TR1 holder who appears to be connected to Merck and Glaxo via previous roles whom added to go above 4.5% in April 20202020 developments May 2020• 26th May , results and £850k placing with a deal with a new major pharmacy client due to be signed imminently • Z .Ali Goes to 5%+ in May 2020 and adds 800k more in the 26th May placing• £150k Innovate Grant for Prostate cancer May 2020June 2020• Confirms another new contract with Bicycle and late stages of signing the major client. July 2020 • signs deal with a large Japanese multi nationalAugust 2020 • confirms via an official tweet that is working with C19 drug developments with other partners • QSP is increasingly used in drugdevelopment to guide research & accelerate the discovery process. At Physiomics, we work with pharma biotech clients to create integrated QSP models & rigorously test them to provide valuable insights.
spudyoulike
21/8/2020
13:23
Keep doing the red ones shoddy.
albert3591
21/8/2020
13:08
Maybe he meant decanting? He is into cheap asda wine after all.
davevt
Chat Pages: Latest  1061  1060  1059  1058  1057  1056  1055  1054  1053  1052  1051  1050  Older

Your Recent History

Delayed Upgrade Clock